July 21, 2026

Off-the-Shelf CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer

Targeted Therapy /

Results from the phase 1a/b TRAVERSE trial suggest that ALLO-316, an off-the-shelf CAR T-cell therapy targeting CD70, may be a promising treatment for patients with advanced clear cell renal cell carcinoma (ccRCC). The study included 51 heavily pretreated patients whose cancer had progressed after checkpoint inhibitors and VEGFR-targeted therapies. In the phase 1b group, ALLO-316 […]

Off-the-Shelf CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer Read More »

10-Year Study Confirms Chemo-Free Option for Follicular Lymphoma

Treatment /

The final 10-year results from the phase 3 RELEVANCE trial show that the chemotherapy-free combination of lenalidomide plus rituximab (R²) provides long-term outcomes similar to standard immunochemotherapy for patients with previously untreated advanced follicular lymphoma. The study included 1,030 adults and followed them for a median of nearly 10 years. Patients treated with R² had

10-Year Study Confirms Chemo-Free Option for Follicular Lymphoma Read More »

Pembrolizumab Plus Denosumab Shows Promising Activity in Pretreated Kidney Cancer

Clinical Trails /

Results from the phase 2 KEYPAD trial suggest that combining pembrolizumab with denosumab may benefit patients with advanced clear-cell renal cell carcinoma (ccRCC) whose cancer progressed after previous VEGFR-targeted therapy. The Australian single-arm study enrolled 59 patients with unresectable or metastatic disease. The combination achieved an objective response rate of 31%, with all responses being

Pembrolizumab Plus Denosumab Shows Promising Activity in Pretreated Kidney Cancer Read More »